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OBJECTIVE—We have previously reported a highly diabeto-
genic CD8 T-cell clone, G9C8, in the nonobese diabetic (NOD)
mouse, speciﬁc to low-avidity insulin peptide B15-23, and cells
responsive to this antigen are among the earliest islet inﬁltrates.
We aimed to study the selection, activation, and development of
the diabetogenic capacity of these insulin-reactive T-cells.
RESEARCH DESIGN AND METHODS—We generated a T-cell
receptor (TCR) transgenic mouse expressing the cloned TCR
V18/V6 receptor of the G9C8 insulin-reactive CD8 T-cell clone.
The mice were crossed to TCRC
/ mice so that the majority of
the T-cells expressed the clonotypic TCR, and the phenotype and
function of the cells was investigated.
RESULTS—There was good selection of CD8 T-cells with a
predominance of CD8 single-positive thymocytes, in spite of
thymic insulin expression. Peripheral lymph node T-cells had a
naïve phenotype (CD44
lo, CD62L
hi) and proliferated to insulin
B15-23 peptide and to insulin. These cells produced interferon-
and tumor necrosis factor- in response to insulin peptide and
were cytotoxic to insulin peptide–coated targets. In vivo, the
TCR transgenic mice developed insulitis but not spontaneous
diabetes. However, the mice developed diabetes on immuniza-
tion, and the activated transgenic T-cells were able to transfer
diabetes to immunodeﬁcient NOD.scid mice.
CONCLUSIONS—Autoimmune CD8 T-cells responding to a
low-afﬁnity insulin B-chain peptide escape from thymic negative
selection and require activation in vivo to cause diabetes.
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T
ype 1 diabetes is a complex, multifactorial dis-
ease in which genetic factors interact with envi-
ronmental modiﬁers to give rise to immune
abnormalities leading to pancreatic -cell dam-
age and destruction. Both CD4 and CD8 T-cells have a
major role in pathogenesis of type 1 diabetes. There are a
number of autoantigens that are recognized by CD8 T-
cells, including proinsulin (PI) (1), islet-speciﬁc glucose-6-
phosphatase catalytic subunit–related protein (IGRP) (2),
dystrophia myotonica kinase (3), and glutamic acid decar-
boxylase (4) in the nonobese diabetic (NOD) animal model
of diabetes. In HLA-A2 transgenic mice, both PI and IGRP
have also been shown to be important targets (5,6).
Furthermore, emerging evidence suggests that CD8 T-cells
in humans also recognize these antigens (7–9), although
their role in pathogenesis is currently unknown.
In humans, CD8 T-cells are present in islet inﬁltrates at
the time diabetes develops (10). CD8 T-cells were predom-
inant in the islet inﬁltrate when diabetes recurred within 6
weeks after transplantation of a hemipancreas from nor-
mal, identical nondiabetic twins into their diabetic cotwins
(11). In NOD mouse studies, it is well established that CD8
T-cells play an important role both in early events leading
to insulitis and diabetes (12,13) as well as in the ﬁnal
effector stage (14) of diabetes development.
PI is an important autoantigen in diabetes, and it has
been suggested that it is the “prime” autoantigen (15)
recognized by CD8 T-cells, CD4 T-cells, and autoantibod-
ies. There is clear evidence that PI is expressed in the
thymus (16) in humans and in mice (17), which inﬂuences
the expression of autoreactive T-cells to PI/insulin. In
humans, although the major histocompatibility complex
(MHC) is the most important genetic susceptibility factor,
the second most important genetic region (IDDM2) is the
insulin 5VNTR region. This controls expression of PI in
the thymus and the pancreas (18). Mice have two types of
insulin, produced as proinsulin 1 (PI1), mainly in the
pancreas, and proinsulin 2 (PI2) in the thymus and pan-
creas. Studies using individual proinsulin PI1
/ and
PI2
/
knockout mice, when backcrossed to the NOD
background, showed that PI1
/ mice have a reduced
incidence of diabetes (19), whereas in PI2
/ mice, diabe-
tes is accelerated with 100% developing diabetes (19,20).
In addition, insulin autoantibody production is increased
in PI2
/ mice, and spleen cells from young PI2
/ ani-
mals have an increased ability to transfer diabetes (20).
Furthermore, when PI2 was overexpressed in the thymus
(and on peripheral antigen-presenting cells [APCs]) on the
MHC class II promoter (PI2tg), the incidence of diabetes
was decreased (21,22). This suggests that PI2 is important
for both central and peripheral tolerance for islet -cells.
We have previously isolated a highly pathogenic CD8
T-cell clone (G9C8) from the islets of young, pre-diabetic
NOD mice that is capable of very rapidly causing diabetes
(5–10 days) upon adoptive transfer to young or irradiated
nondiabetic NOD mice (23). The autoantigen is an insulin
B-chain peptide (amino acids 15–23 [B15-23]) (1). The
epitope is common to both mouse insulins (and is also
conserved in human insulin) and is restricted by MHC-K
d.
The insulin peptide is recognized by a small population of
cells present in the very early stages of the islet inﬁltrate,
identiﬁed using a K
d–B15-23 tetramer (1) and is found in
mice aged 5 weeks (1,24). Subsequently, other speciﬁc-
ities such as IGRP become increasingly dominant (24–26),
and this insulin-speciﬁc population becomes a smaller
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To further study the selection and activation of this early
population of CD8 T-cells, we have generated a T-cell
receptor (TCR) transgenic mouse in which the T-cells
express the receptor of the highly pathogenic G9C8 clone.
Unlike other CD8 TCR transgenic mice that recognize
higher-afﬁnity MHC binding peptides of IGRP (2,27), G9C8
T-cells have low avidity, and G9 transgenic mice do not
develop spontaneous diabetes. However, transgenic G9
cells can be highly diabetogenic after activation both in
vitro and in vivo.
RESEARCH DESIGN AND METHODS
Generation of insulin-reactive TCR transgenic mice. Insulin-speciﬁc TCR
transgenic mice were generated by isolating TCR genomic DNA from G9C8
cloned T-cells (23), which have previously been shown to have speciﬁc
reactivity to amino acids 15–23 of the insulin B-chain (1). TCR (V18S1 J18
C)- and  (V6S1 D1.1 J2.3 C1)-chain DNA was puriﬁed and cloned into
pTcass and pTcass constructs (28), respectively, kindly provided by D.
Mathis. The cloned constructs were injected directly into NOD ova to generate
independent TCR and  founder lines in the Yale Diabetes Endocrinology
Research Center (DERC) transgenic core (R.A. Flavell, Yale School of
Medicine), which were intercrossed to produce  TCR transgenic mice
(G9NOD). Three independent founder lines each of TCR (lines 17, 22, and 24)
and  (lines 1, 2, and 3) were generated, and  lines 17, 22, and 24 were
crossed with each of  lines 2 and 3. Results with each of these lines was
similar in terms of selection and functional phenotype (data not shown), and,
thus, TCR line 22 and TCR line 2 were chosen for all subsequent studies.
To generate repertoire-restricted  TCR transgenic mice, G9C
/.NOD
mice were generated by crossing the  TCR transgenic mice to NOD.C
/
mice. The NOD.C
/ mice were generated by backcrossing TCR.C
/
mice (B6/129 background; kindly provided by A.C. Hayday) (29) 20
generations to NOD/Caj mice in the laboratory of R.S. Sherwin (Yale
University). G9RAG
/.NOD mice were generated by crossing the 
TCR transgenic mice to NOD.RAG2
/ mice, generated by backcrossing
RAG2
/ mice (kindly provided by D. Schatz, Yale University) to NOD/Caj
mice 12 generations. To generate G9C
/.RIP-B7.1 NOD mice, the
RIP-B7.1 mice were 10 generations backcrossed to NOD.C
/ mice and
intercrossed to generate NOD.C
/RIP-B7.1 mice and then crossed with
the G9C
/.NOD mice to generate G9C
/.RIP-B7.1 NOD mice. NOD.scid
mice were originally obtained from The Jackson Laboratories but were
bred for many years at Yale University. The mice were housed in
microisolators or scantainers in barrier rooms. All procedures were
performed in accordance with the protocols approved by the U.K. Home
Ofﬁce or institutional animal care and use committee at Yale University.
Flow cytometry. Single-cell suspensions of 0.1–1  10
6 cells were stained for
various cell surface markers (rat anti-murine CD8; CD4, CD62L, and CD44).
FcRs were blocked with anti-CD16 (2.4G2; provided by the late C.A. Janeway),
and cells were stained for surface markers. Intracellular staining was per-
formed on cells cultured for 15 h with differing concentrations of peptide, for
interferon (IFN)- and tumor necrosis factor (TNF)-, after cell surface
staining with anti-CD8 following the BD Bioscience protocol. They were
analyzed by ﬂow cytometry using a FACSCalibur, and results were analyzed
using CellQuest (BD Bioscience) or FlowJo (Tree Star) software. All antibod-
ies were purchased from BD Bioscience, except anti-murine CD8-allophyco-
cyanin (Caltag Laboratories).
Cells were stained with K
d-B15-23-PE tetramer or control K
d-listeriolysin
(LLO) 91-99-PE tetramer (obtained from the National Institutes of Health
Tetramer Facility) for1ha t4°C. Anti–CD8–ﬂuorescein isothiocyanate was
added for the last half hour. The cells were then washed and analyzed by ﬂow
cytometry.
Enriched CD8 T-cells from splenocytes of G9C
/.NOD mice were
labeled with 5 	mol/l carboxyﬂuorescein succinimidyl ester (CFSE) for 10
min at 37°C and washed with ice-cold RPMI-1640 with 5% FCS and then with
0.9% normal saline. Ten million cells were resuspended in 0.9% normal saline
and transferred intravenously to 4- or 6-week-old NOD mice. The spleen,
pancreatic, axillary, and mesenteric lymph nodes were removed 6–10 days
posttransfer, and CFSE dilution was analyzed by ﬂow cytometry after staining
with anti–CD8-allophycocyanin and anti–CD69-phycoerythrin.
Proliferation and cytotoxicity assays: proliferation. Insulin-reactive CD8
T-cells from 5- to 8-week-old G9C
/.NOD mice were cocultured with bone
marrow–derived dendritic cells and B15-23 peptide or inﬂuenza hemagglutinin
peptide IYSTVASSL (control) for peptide responses in RPMI complete me-
dium. Similarly, soluble insulin or keyhole limpet hemocyanin (control) was
used as antigen for protein cross-presentation responses. CD8 T-cells were
puriﬁed from splenocytes of G9C
/.NOD mice using positive selection
beads (Miltenyi Biotec) with 95% purity. After 3 days of incubation, cells
were pulsed with [
3H]thymidine for 14 h to determine proliferation.
Cytotoxicity. CD8 T-cells puriﬁed from 5- to 8-week-old G9C
/.NOD mice,
used directly ex vivo or prestimulated for 24 h with 1 	g/ml insulin B15-23
peptide, were harvested and further cocultured with 10
45 1 Cr-sodium chro-
mate (Amersham)-labeled P815 cells together with B15-23 insulin peptide at
an effector-to-target (E:T) ratio of 10:1 for 16 h. Speciﬁc lysis was calculated
as [(cytotoxic release  min)/(max  min)]  100%, where the minimal
release (min) corresponded to the spontaneous lysis, and the maximal lysis
corresponded to lysis induced by addition of Triton-X100 (max).
In vivo immunization. G9C
/.NOD mice were immunized intraperitone-
ally with 50 	g B15-23 peptide together with different concentrations of CpG
1826 oligonucleotides (Coley pharmaceuticals). Nine to twenty-one days later,
a further injection of the same dose was given. Controls were injected with
either 50 	g B15-23 peptide or the different doses of CpG alone.
Diagnosis of diabetes. Diabetes was detected by initially testing for glyco-
suria and conﬁrmed by blood glucose measurements 13.9 mmol/l/l.
Adoptive transfer of diabetes. A total of 5–7  10
6 puriﬁed CD8 T-cells
from G9C
/.NOD mice, either taken directly ex vivo or preactivated by
CpG-matured bone marrow–derived dendritic cells and insulin B15-23 pep-
tide, were washed, resuspended in a volume of 200 	l of normal saline, and
transferred intravenously to 6-week-old NOD.scid mice, 3-week-old NOD
mice, and 6-week-old NOD mice. CD4 T-cells puriﬁed either from young
6-week-old mice (10
7) or from mice that had become diabetic (4–10  10
6)
were transferred intravenously to 3- to 4-week-old G9C
/.NOD mice.
Histology. Pancreata were harvested and ﬁxed, and immunohistochemistry
was performed as previously described (30). Insulitis was measured in 6-, 9-,
12-, 15-, 20-, and 25-week-old mice (n 
 3–4 each). Sections were stained with
hematoxylin and eosin (Vector Laboratories) and scored for insulitis.
RESULTS
TCR transgenic cells are selected in the thymus. The
transgenic TCR in G9NOD mice is expressed in both
thymus and the periphery, and there is an increased
proportion of CD8 T-cells and reduced CD4 T-cells com-
pared with nontransgenic NOD mice (Fig. 1A–E). The
allelic exclusion at the TCR chain locus is poor (Fig. 1C
and F), and other TCR chains can be selected as shown
by a high frequency of expression of the TCR chains 2, 3,
8, and 11, which were identiﬁed by ﬂow cytometry. Similar
results were obtained from different TCR transgenic
lines (combination of mice from three different TCR
founder lines with two different TCR founder lines; data
not shown). Thus, to study the transgenic TCR of the
original G9C8 T-cell clone, we selected one TCR trans-
genic line and crossed the G9NOD mice with TCRC
/
and RAG2
/ mice in order to study the characteristics of
the repertoire-restricted TCR transgenic cells.
Despite thymic expression of preproinsulin 2 (31), the
G9C
/ and G9RAG
/ transgenic cells are clearly se-
lected in the thymus (Fig. 2A and F). There is peripheral
expansion of the T-cells in the spleen and lymph nodes
(illustrated in Fig. 2B and C and Fig. 2G and H, respec-
tively), and, as expected, the cells express TCRV6
(shown in Fig. 2D and I), and the majority of cells
expressing CD8 are also positive for K
d-insB15-23 tetramer
staining (Fig. 2E).
G9C
/ TCR transgenic cells respond to antigen by
proliferation, cytokine production, and cytotoxicity.
The T-cells demonstrate antigen-speciﬁc cytotoxicity di-
rectly ex vivo (shown in Fig. 3A), but their ability to kill in
vitro targets is enhanced by nearly two logs after culturing
the cells with antigen, indicating that the cells are rela-
tively naïve when derived directly ex vivo from the trans-
genic mouse (Fig. 3A). They produce IFN- and TNF- in
response to antigenic peptide (Fig. 3B). As expected, they
proliferate to insulin peptide (Fig. 3C) and also respond to
insulin protein cross-presented by bone marrow–derived
F.S. WONG AND ASSOCIATES
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peptide is naturally processed and presented. Thus, the
transgenic G9 cells maintain the immunological function
of their parental G9C8 clone.
TCR transgenic cells cause insulitis but not diabetes.
In view of the highly pathogenic nature of the original
G9C8 T-cell clone, we tested whether the mice developed
insulitis. We found that in the G9C
/ TCR transgenic
mice, a few islets have a large inﬁltration by CD8 T-cells
but also by B-cells and CD4 T-cells (online appendix
Fig. 1 [available at http://diabetes.diabetesjournals.org/
cgi/content/full/db08-0800/DC1]). However, inﬁltration is
only seen after 15 weeks of age, and even then most of the
islets do not become inﬁltrated (islets examined from mice
at 6, 9, 12, 15, 20, and 25 weeks of age) (insulitis scores
shown in online appendix Table 1). Neither the G9C
/
TCR mice (30 mice observed until 35 weeks of age) nor the
G9RAG
/ TCR mice developed spontaneous diabetes,
similar to the three lines of G9NOD mice observed that
were not on the C
/ background.
Role of CD4 T-cells. As can be seen from Fig. 2, although
there are fewer CD4 T-cells in the G9C
/.NOD mice
compared with the G9NOD mice (shown in Fig. 1), the
question arises as to whether these CD4 T-cells contain a
regulatory T-cell population that prevented the G9C
/
.NOD mice from developing diabetes. To examine
whether the CD4 T-cell population inhibited the CD8
T-cells in vitro, proliferation assays were performed that
showed that G9C
/.NOD CD4 T-cells can proliferate to
the insulin B15-23 peptide but at a lower level. Further-
more, they do not inhibit the CD8 T-cells from proliferat-
ing when they are added to CD8 T-cells in the proliferation
assay but rather enhance the proliferation (shown in Fig.
4A). However, to test further whether these cells were
having an inhibitory effect in vivo, we depleted both total
CD4 T-cells (n 
 6) using anti-CD4 antibody and
CD4
CD25
 T-cells (n 
 3) using anti-CD25 antibody
injected four times over a period of 6 weeks starting at 4
weeks of age. The experiments were controlled by injec-
tion of rat isotype control antibody (n 
 3). Efﬁcacy of
depletion was shown by testing peripheral blood just
before the next injection, and at each time point in mice
injected with anti-CD4 or anti-CD25, the CD4 or
CD4
CD25
 T-cells were 1% in the peripheral blood
(data not shown). None of the mice in any of the groups,
observed until 20 weeks of age, developed diabetes. Thus,
the lack of diabetes did not appear to be related to CD4
regulatory T-cells.
FIG. 1. Comparison of thymocytes and splenocytes from G9NOD transgenic mice and nontransgenic NOD mice. A–C: Cells from G9NOD transgenic
mice. D–F: Cells from nontransgenic NOD mice. A and D: Thymocytes single-positive CD4 and anti-CD8. B and E: Splenocytes stained with
anti-CD4 and anti-CD8. C and F: Splenocytes stained with anti-CD8 and a pool of anti-V2, -3, -8, and -11. The results are representative of 15
transgenic mice in more than ﬁve independent experiments. The mean (SD) values for the cell populations are as follows: A: CD4 3.46 (1.71); CD8
5.89 (2.28). B: CD4 17.38 (4.91); CD8 20.35 (3.77). C: CD8V2, -3, -8, -11 negative 20.0 (4.1); CD8V2, -3, -8, -11 positive 3.8 (1.9). D: CD4 10.2
(1.9); CD8 4.7 (0.7). E: CD4 40.63 (5.6); CD8 17.07(1.9). F: CD8V2, -3, -8, -11 negative 15.36 (1.03); CD8V2, -3, -8, -11 positive 1.85 (0.08).
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quired, G9C
/.NOD mice were infused with either puri-
ﬁed CD4 T-cells from young NOD mice or with CD4 T-cells
from diabetic NOD mice. None of the G9C
/.NOD mice
given CD4 cells from young NOD mice developed diabetes,
whereas diabetes occurred in G9C
/.NOD mice trans-
ferred with CD4 T-cells from the diabetic NOD spleens
(shown in Fig. 4B). Thus, activated but not nonactivated
polyclonal CD4 T-cells are able to promote diabetes in the
G9C
/.NOD mice.
TCR transgenic cells become highly diabetogenic af-
ter activation in vitro or in vivo. The G9 cells in TCR
transgenic mice express a naïve phenotype and function,
and the G9C
/.NOD mice do not develop spontaneous
diabetes. Therefore, we sought to test whether activation
of the insulin-reactive transgenic T-cells, other than by
adding activated CD4 T-cells, could cause diabetes. We
injected the mice with insulin B15-23 peptide together with
type B CpG oligonucleotides and showed that this ap-
proach promoted very rapid diabetes development (Fig.
5A). This was a speciﬁc response requiring peptide, as
CpG alone did not induce disease (data not shown).
Similarly, the CpG was required to activate the APCs, as
injection with peptide alone also did not induce disease
(data not shown). The combined CpG and peptide injec-
tion activated G9 transgenic T-cells, and their activation
proﬁle shows downregulation of CD62L and upregulation
of CD44 (illustrated in Fig. 5B). On development of diabe-
tes, most islets were seen to have extensive inﬁltration and
destruction, whereas little or no insulitis was seen in the
islets of mice that were immunized with either CpG or
peptide alone (shown in Fig. 5C).
Furthermore, the G9C
/.NOD CD8 T-cells could be-
come potent diabetogenic T-cells after activation with
bone marrow–derived dendritic cells that are matured by
CpG. Following a 3-day culture with CpG-matured bone
marrow dendritic cells in the presence of insulin B15-23
peptide, the G9C
/.NOD CD8 transgenic cells were
able to transfer diabetes rapidly without the aid of CD4
T-cells into 6-week-old NOD.scid mice (Fig. 6), recapit-
ulating the phenotype of the original CD8 T-cell clones
(23). G9C
/.NOD CD8 T-cells that were not preacti-
vated did not transfer diabetes when a similar number of
nonactivated G9C
/.NOD CD8 T-cells were transferred
and observed for 12 weeks after transfer (data not shown).
This suggests that activation increases the functional avidity
of G9 cells (shown by the data in Fig. 3A), and this enhances
their cytotoxic function and diabetogenicity.
Activation of insulin-reactive CD8 T-cells by increas-
ing antigen presentation within islets. We have previ-
ously suggested that expression of the costimulator B7-1
on the islets is able to activate low-avidity T-cells and
cause accelerated diabetes (30). To test whether the
coexpression of RIP-B7.1 could induce diabetes in
G9C
/.NOD mice, we crossed the G9C
/.NOD mice
to RIP-B7.1.C
/ mice that had been generated for this
purpose. In the presence of B7.1 in the pancreas, the
G9C
/.NOD mice developed spontaneous diabetes
(shown in Fig. 7). To determine that this was a periph-
eral effect and not related to changes in selection of the
G9TCR T-cells, we had previously demonstrated that the
naïve G9TCR CD8 T-cells from G9C
/.NOD mice
could readily transfer diabetes to NOD.scid mice that
expressed RIP-B7.1 (30), indicating that the naïve
G9TCR CD8 T-cells can be activated in situ in the islets
and become highly pathogenic. These results support
the data presented earlier that increasing the functional
avidity of G9TCR T-cells through activation can pro-
mote diabetogenicity of transgenic G9 T-cells.
Activation of insulin-reactive CD8 T-cells in vivo in
NOD mice. To investigate the homing and activation of
insulin-reactive G9 CD8 T-cells in vivo, we used CFSE-
β 
FIG. 2. Phenotype of G9C
/.NOD mice and G9RAG
/.NOD mice. G9C
/.NOD thymocytes (A), splenocytes (B), and PLN cells (C) were
stained with anti-CD4 and -CD8. D: PLN cells were stained with anti-V6 and CD8. E: Gated CD8 T-cells were stained with K
d-B15-23 (bold line)
and control K
d-LLO 91–99 (dotted line) tetramer, respectively. G9RAG
/.NOD thymocytes (F), splenocytes (G), and PLN cells (H) were stained
with anti-CD4 and -CD8. I: PLN cells were stained with anti-V6 and CD8. The results represent three independent experiments. The mean (SD)
values for the distribution of cell populations are as follows: A: CD4 1.43 (0.42); CD8 5.1 (1.6). B: CD4 8.28 (1.35); CD8 21.14 (4.62). C: CD4 6.28
(0.57); CD8 52.18 (9.26). F: CD4 0.85 (0.44); CD8 2.93 (1.22). G: CD4 2.21 (2.16); CD8 33.42 (6.94). H: CD4 1.18 (0.66); CD8 68.7 (13.32).
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/.NOD mice
transferred into 4- to 6-week-old NOD mice and analyzed
CFSE dilution in different lymphoid tissues. We showed
that the G9 CD8 T-cells proliferated, as shown by the
decrease in CFSE staining, mainly in the pancreatic lymph
nodes (PLNs) but not in the spleen or other lymph nodes.
More importantly, the dividing G9 CD8 T-cells express
early activation marker CD69 (Fig. 8). This indicates that
NOD mice as young as 4 weeks of age have the capability
of activating G9-like cells in the pancreatic lymph nodes.
However, this single transfer of nonactivated cells into 4-
to 6-week-old NOD mice did not result in acceleration of
diabetes, when the mice were followed to 15 weeks (the
age by which acceleration of disease would be observed).
DISCUSSION
Our study has shown that G9 TCR transgenic CD8 T-cells
that react to an insulin B-chain peptide B15-23, one of the
earliest antigenic epitopes to which CD8 T-cells respond
(at 3–4 weeks of age), are selected in the thymus. Once
released in the periphery, they can be stimulated to
become highly pathogenic. The G9 cells are activated by
the B15-23 peptide, which has low-afﬁnity binding to the
MHC-K
d, and, interestingly, as expected from a naturally
processed and presented peptide, transgenic G9 cells can
be stimulated by whole insulin protein cross-presented by
dendritic cells. Although G9C
/ mice do not spontane-
ously develop diabetes, they do so when naturally acti-
vated polyclonal CD4 T-cells from diabetic NOD mice are
transferred, indicating a requirement for CD4 T-cells.
Moreover, when transgenic G9 cells are fully activated in
vitro, they gain potent diabetogenicity and cause diabetes
in immunodeﬁcient NOD.scid mice, without additional
CD4 T-cell help, recapitulating the phenotype of the pa-
rental clone cells. Importantly, these cells can also be
activated in vivo and cause rapid diabetes development by
providing exogenous insulin peptide in the presence of
immunostimulatory CpG. A similar effect can be achieved
if the costimulatory molecule B7.1 is expressed within the
islets.
Why are these low-avidity T-cells present in the NOD
mouse and where are the cells stimulated in vivo? Re-
cently, a multitude of peripheral antigens were shown to
be expressed in medullary epithelial cells of the thymus
due to the autoimmune regulator gene Aire (32). High-
avidity T-cells are removed at the cortico-medullary junc-
tion, protecting against autoimmunity, and deﬁciency of
Aire leads to widespread multiorgan autoimmune disease
(32). However, some autoreactive T-cells still escape from
the thymus, and, using model antigens, it has been shown
that low-avidity T-cells are not deleted in the thymus
(33,34). PI2 is expressed in the thymus (17,35), and even
with the thymic expression, G9-like low-avidity insulin-
reactive T-cells can clearly escape from negative selection.
Furthermore, in our studies, low-avidity insulin-speciﬁc
CD8 T-cells are found in the periphery and are not subject
to peripheral deletion. As with other islet autoantigen-
reactive reactive CD8 (36) and CD4 (37) T-cells in the NOD
µ µ
µ µ
γ
α
FIG. 3. Functional responses of puriﬁed CD8 T-cells from G9C
/.NOD mice. A: Cytotoxic assay of insulin-reactive CD8 T-cells directly ex vivo
(E) from G9C
/.NOD mice compared with precultured cells (F) in response to increasing B15-23 peptide concentrations at an E:T ratio of 10:1.
B: Intracellular IFN- and TNF- production in response to increasing concentrations of insulin B15-23 peptide after a 40-h culture. C:
3H-Thymidine incorporation proliferation assay of splenocytes from G9C
/.NOD mice in response to B15-23 peptide and to inﬂuenza
hemagglutinin (ﬂu HA) control peptide. F, Ins B15-23; E,ﬂ uH A .D:
3H-Thymidine incorporation proliferation assay of splenocytes from
G9C
/.NOD mice in response to cross-presented insulin protein or control KLH. The results were from one of four independent experiments.
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in the pancreatic lymph nodes compared with the spleen
and other lymph nodes, including the mesenteric lymph
nodes. However, our earlier study and those of others
(1,3,24) demonstrated that the numbers of these cells
remain small in lymphoid tissue, but they are measurable
in the islets from an early age. It is possible that only in the
islets is sufﬁcient antigen presented to these cells for their
expansion, as a relatively high concentration of the low-
afﬁnity peptide is required to stimulate them. These cells
can be sufﬁciently activated in the pancreatic draining
lymph nodes, possibly by dendritic cells that stimulate
them to trafﬁc to the islets where a higher concentration of
the insulin peptide within the islets induces G9 cell expan-
sion and damage to the islets in the early phases. However,
other speciﬁcities that may be of higher avidity, such as
IGRP-reactive CD8 T-cells, expand more and overtake
these cells in number and percentage representation in the
islet inﬁltrate in later phases of the disease development.
Why do these TCR transgenic mice not develop diabetes
spontaneously? In the NOD mouse, different islet antigen–
speciﬁc T-cells are likely to be involved in early phases of
the autoimmune process, and it is likely that each may
amplify the autoimmune response of the others by produc-
ing interleukin-2 locally, which may also increase cells by
homeostatic expansion (38). Insulin, as a -cell–speciﬁc
autoantigen, is very different from other -cell–associated
antigens. In addition to MHC class I–restricted antigen
presentation by the -cells, insulin is secreted by islet
-cells in response to high glucose from the portal system
and circulates in the body at low concentrations, depen-
dent on ambient glucose. The peptide recognized by the
insulin-speciﬁc T-cells in this study has a low afﬁnity of
binding to H2-K
d molecules (39). The widely studied 8.3
TCR transgenic T-cells recognize an epitope of IGRP
206-214, an enzyme within -cells with high avidity (40).
Much less is known of the other autoantigen, dystrophia
myotonica kinase, which stimulates the CD8 T-cells from
the TCR transgenic mouse AI-4 (3). Both of these mice
develop diabetes spontaneously, although 8.3TCR trans-
genic mice develop more diabetes in the presence of CD4
T-cells (27), whereas this is not a requirement for the AI-4
transgenic mouse (41). In contrast, for CD4 TCR trans-
µ
FIG. 4. The role of CD4 T-cells. A:
3H-Thymidine incorporation prolif-
eration assay of CD8, CD4, and mixed CD8 and CD4 splenocytes from
G9C
/.NOD mice in response to B15-23 peptide G9C
/. B: Adop-
tive transfer of puriﬁed CD4 T-cells of splenocytes from diabetic NOD
intravenously into 4-week-old G9C
/.NOD mice (n  16). No diabe-
tes occurred in mice adoptively transferred with CD4 T-cells puriﬁed
from young NOD mice (n  5). P < 0.018 when both groups were
compared. The mice were tested weekly for glycosuria and diabetes
conﬁrmed by blood glucose of >13.9mmol/l.
FIG. 5. Activated CD8 T-cells from G9C
/.NOD mice cause diabetes. A:
G9C
/.NOD mice were immunized with B15-23 peptide (50 g) together
with CpG oligonucleotides at different doses (two injections, 9–21 days
apart). Diabetes was seen after the second injection in the majority of
mice and the graph illustrates the mice, following the second injection,
immunized with peptide plus 65 g CpG (F), peptide plus 100 g CpG (E),
and peptide plus 195 g CpG (‚). Two of four mice immunized with
peptide, and high-dose CpG (195 g) actually developed diabetes before
the second injection and the remaining two mice are shown in the graph.
None of the control mice injected with peptide alone (n  11) or the
various doses of CpG alone (n  13) developed diabetes (data not
shown). P < 0.0001 when all groups were compared. B: Flow cytometry of
spleen cells from a nonimmunized G9C
/.NOD mouse, gated on CD8
T-cells, shown in the thin line, compared with cells from a diabetic mouse
after CpG and peptide immunization, shown in the thick line. The upper
panel shows upregulation of CD44 and the lower panel illustrates down-
regulation of CD62L. C: Histology showing sections from diabetic G9C
/
.NOD mouse immunized with CpG and peptide (top row), CpG alone
(middle row), and peptide alone (bottom row), stained with anti-CD8,
anti-CD4, and anti-B220 (B-cells). (A high-quality representation of this
ﬁgure is available in the online issue.)
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the highly pathogenic BDC2.5 cells develop spontaneous
diabetes when expressed on a C57BL/6 genetic back-
ground, but the incidence of diabetes is much lower on the
NOD genetic background (42), although it is sharply
increased when regulatory T-cells are removed by expres-
sion on a NOD.scid genetic background. Similarly, the 4.1
TCR transgenic mice recognizing an unknown islet antigen
develop diabetes a little earlier on a RAG2
/ genetic
background (27), and the 12-4.1 TCR transgenic mice,
recognizing an insulin peptide only, develop diabetes on a
RAG2
/ genetic background (43). Not surprisingly, these
mice have varying phenotypes, differing between CD4 and
CD8 transgenic T-cells that are likely to reﬂect important
aspects of the biology of the native cells within the normal
mice and also interactions with other cells of the immune
system, emphasizing the need to study more than one
speciﬁcity of pathogenic T-cell.
The fact that the G9TCR transgenic mice do not
develop spontaneous diabetes is highly reminiscent of
the LCMVgp/p14 double transgenic mouse, in which a
transgenic TCR that recognizes a peptide of lymphocytic
choriomeningitis virus (LCMV) glycoprotein was coex-
pressed with the target LCMVgp as an autoantigen in the
pancreas using the rat insulin promoter (RIP) (44). In that
model, the TCR transgenic cells were “ignorant” and
diabetes did not occur spontaneously but could be in-
duced to occur on infection with LCMV or administration
of the LCMVgp peptide with lipopolysaccharide (44). Here,
we show that this mechanism can operate for a naturally
occurring autoantigen (insulin) and low-avidity (G9) T-
cells. In the NOD mouse, which develops diabetes spon-
taneously, infection is clearly not the strong stimulus
necessary for activation of low-avidity cells, and, indeed,
many infections prevent diabetes in these mice. However,
there may be endogenous stimuli of the innate immune
system that could activate low-avidity cells (45,46), leading
to further immune activation in both diabetes and other
autoimmune diseases. Indeed, we have shown that activa-
tion, using a ligand for TLR9, can stimulate the insulin-
reactive cells to become highly potent cytotoxic T-cells.
The challenge will be to identify how this process occurs
in vivo.
What relevance does this low-avidity T-cell have in
diabetes? A recent study (15) showed that diabetes was
inhibited if NOD mice were deﬁcient in both PI1 and PI2
but expressed a transgenic insulin that was mutated at
position 16 of the B-chain. The alteration of B16, in fact,
will undoubtedly affect both pathogenic CD4 cells recog-
nizing insulin B9-23 (47) as well as pathogenic CD8 T-cells
recognizing insulin B15-23 (23). This B16 mutation over-
laps the CD8 epitope B15-23 and is the major MHC-K
d
binding residue for the B15-23 epitope (39). Its effects in
protecting against diabetes were likely to be linked to
removing not only the CD4 epitope affecting diabetogenic
CD4 cells but also the CD8 epitope, abolishing the ability
of G9-like CD8 T-cells to recognize and bind natural
B15-23, a weak binder to the MHC-K
d (39). Thus, although
the study by Nakayama et al. (15) did not distinguish
effects on CD4 insulin– versus CD8 insulin–reactive T-
cells, CD8 T-cells are highly likely to be affected (48,49).
G9-like cells are present in the islets at a very early stage
of islet inﬁltration (1), and others have shown that reac-
FIG. 6. Adoptive transfer of puriﬁed activated G9C
/.NOD CD8
T-cells into NOD.scid mice. G9C
/.NOD CD8 T-cells were puriﬁed
and cultured with matured bone marrow–derived dendritic cells to-
gether with 0.5 g/ml insulin B15-23 peptide for 3 days. After washing,
the cells were intravenously injected into 6-week-old NOD.scid mice
(n  8). Mice were tested daily for glycosuria and diabetes conﬁrmed
by blood glucose >13.9mmol/l.
FIG. 7. Diabetes incidence in G9C
/.RIP-B7.1 NOD mice. G9C
/.NOD
mice that also expressed RIP-B7.1 transgene (F, n  18) were compared
with nontransgenic G9C
/.NOD mice (E, n  20) and observed for
diabetes. Mice were tested weekly for glycosuria and diabetes conﬁrmed
by blood glucose >13.9 mmol/l (P < 0.0001).
FIG. 8. Insulin-reactive CD8 T-cells proliferate only in PLNs but not in
the spleen, MLN, or ALN when adoptively transferred into NOD mice.
CFSE-labeled puriﬁed G9C
/.NOD CD8 T-cells were injected iv into
4-week-old NOD mice and the lymphoid tissue extracted and cells
analyzed in PLNs (A) and spleen (B). The cells were gated on CD8
T-cells, and CFSE-labeled cells, costained with anti-CD69, are shown
from PLNs (A) and spleen (B). Percentage proliferation of divided cells
is shown after gating on CD8 T-cells from PLNs (C) and spleen (D).
Proliferation in MLN and ALN was similar to spleen (data not shown).
All groups were compared by ANOVA P  0.014.
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far identiﬁed when compared with the more dominant
IGRP-reactive T-cells (24). Cytotoxic T-cells speciﬁc for
IGRP were not detected in PItg NOD mice that were
tolerant to PI, suggesting that immune responses against
PI are required for IGRP-speciﬁc T-cells to develop (50).
The current study reports insulin-reactive CD8 transgenic
T-cells can cause rapid diabetes after activation, and this
study does not address whether insulin is a “prime autoan-
tigen” for CD8 T-cells in NOD mice. Further work is
ongoing to establish whether these cells require “help”
from CD4 insulin–reactive cells or whether other speciﬁc-
ities can provide this.
In conclusion, we have shown that a CD8 T-cell respon-
sive to a natural peptide of insulin, a major autoantigen in
autoimmune diabetes, is selected in the thymus and can
become highly pathogenic once activated in the periphery,
causing diabetes. These T-cells are “ignorant” in a naïve
state, but this can be readily overcome by stimuli that
include direct activation or activation of antigen-present-
ing cells, either in pancreatic lymph nodes or in the islets.
CD4 T-cells are likely to play a signiﬁcant role, and this is
currently under investigation. Further experiments aim to
identify the endogenous stimulators that facilitate the
“switch” of naïve and “ignorant” G9 cells into potent
-cell–destructive effector cells in the NOD mouse. Our
study provides an important model not only for the study
of immunopathogenic role of insulin-speciﬁc CD8 T-cells
in autoimmune diabetes but also for better design of
insulin-based immunotherapy.
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